Stocktoria
Arcturus Therapeutics Holdings Inc. ARCT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-05-22
Arcturus Therapeutics Holdings Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $82.0M | $152.3M | $166.8M | $206.0M | $12.4M |
| R&D expense | $112.2M | $195.2M | $192.1M | $147.8M | $173.8M |
| Operating income | -$76.3M | -$95.7M | -$78.2M | $12.2M | -$202.9M |
| Income tax | — | -$4,000 | $1.8M | $1.3M | — |
| Net income | -$65.8M | -$80.9M | -$29.7M | $9.3M | -$203.7M |
| EPS (diluted) | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 |
| Operating cash flow | -$74.3M | -$59.7M | -$18.1M | $32.0M | -$135.0M |
| Free cash flow | -$74.5M | -$60.4M | -$21.0M | $24.3M | -$138.4M |
| Cash & equivalents | $230.9M | $237.0M | $292.0M | $391.9M | $370.5M |
| Total assets | $271.1M | $344.1M | $429.4M | $450.4M | $392.8M |
| Total liabilities | $57.2M | $103.1M | $150.9M | $180.1M | $164.6M |
| Shareholders' equity | $214.0M | $241.0M | $278.5M | $270.3M | $228.2M |
Source: SEC EDGAR filings · CIK 0001768224 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.